BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Paroxysmal Nocturnal Hemoglobinuria readouts · AssetMemo
X-WR-CALDESC:Upcoming phase 1/2 and later readouts in Paroxysmal Nocturnal 
 Hemoglobinuria\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06449001-885@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Ultomiris (Ravulizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Ultomiris (Ravulizumab)\, phase 3\, Paroxysmal Nocturnal Hemogl
 obinuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or
  Eculizumab in Pediatric Participants With PNH Who Have Clinically Signifi
 cant Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. T
 his is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and 
 it can move.\nDrug page: https://assetmemo.bio/drug/ravulizumab#upcoming-e
 vents\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/ravulizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06449001-886@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20270528
DTEND;VALUE=DATE:20270529
SUMMARY:Soliris (Eculizumab): Phase 3 readout est. (NCT06449001)
DESCRIPTION:Soliris (Eculizumab)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of Danicopan as Add-on Treatment to Ravulizumab or Ec
 ulizumab in Pediatric Participants With PNH Who Have Clinically Significan
 t Extravascular Hemolysis\nEstimated primary completion: 28 May 2027. This
  is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and it 
 can move.\nDrug page: https://assetmemo.bio/drug/eculizumab#upcoming-event
 s\nRegistry record: https://clinicaltrials.gov/study/NCT06449001
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05731050-886@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20270930
DTEND;VALUE=DATE:20271001
SUMMARY:Soliris (Eculizumab): Phase 2 readout est. (NCT05731050)
DESCRIPTION:Soliris (Eculizumab)\, phase 2\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of NM8074 in Soliris-Treated Patients With Paroxysmal
  Nocturnal Hemoglobinuria (PNH)\nEstimated primary completion: September 2
 027. This is a ClinicalTrials.gov estimate\, not a confirmed readout date\
 , and it can move.\nDrug page: https://assetmemo.bio/drug/eculizumab#upcom
 ing-events\nRegistry record: https://clinicaltrials.gov/study/NCT05731050
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04747613-887@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20271018
DTEND;VALUE=DATE:20271019
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT04747613)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Long-term Safety and Tolerability of Iptacopan in Patients 
 With Paroxysmal Nocturnal Hemoglobinuria\nEstimated primary completion: 18
  October 2027. This is a ClinicalTrials.gov estimate\, not a confirmed rea
 dout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/iptaco
 pan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04747613
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06238544-11076@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20271231
DTEND;VALUE=DATE:20280101
SUMMARY:HRS-5965: Phase 2 readout est. (NCT06238544)
DESCRIPTION:HRS-5965\, phase 2\, Paroxysmal Nocturnal Hemoglobinuria.\nStud
 y: Long-term Safety and Tolerability of HRS-5965 in Patients With Paroxysm
 al Nocturnal Hemoglobinuria\nEstimated primary completion: December 2027. 
 This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, and
  it can move.\nDrug page: https://assetmemo.bio/drug/hrs-5965#upcoming-eve
 nts\nRegistry record: https://clinicaltrials.gov/study/NCT06238544
URL:https://assetmemo.bio/drug/hrs-5965#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05744921-5167@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20281010
DTEND;VALUE=DATE:20281011
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT05744921)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Paroxysmal Nocturnal Hemoglobinu
 ria.\nStudy: A Study in Adult Patients With Paroxysmal Nocturnal Hemoglobi
 nuria (PNH) to Evaluate How Safe Long-term Treatment With Pozelimab + Cemd
 isiran Combination Therapy is and How Well it Works\nEstimated primary com
 pletion: 10 October 2028. This is a ClinicalTrials.gov estimate\, not a co
 nfirmed readout date\, and it can move.\nDrug page: https://assetmemo.bio/
 drug/pozelimab#upcoming-events\nRegistry record: https://clinicaltrials.go
 v/study/NCT05744921
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT04901936-907@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20281231
DTEND;VALUE=DATE:20290101
SUMMARY:Empaveli (Pegcetacoplan): Phase 2 readout est. (NCT04901936)
DESCRIPTION:Empaveli (Pegcetacoplan)\, phase 2\, Paroxysmal Nocturnal Hemog
 lobinuria.\nStudy: A Study of Pegcetacoplan in Pediatric Patients With Par
 oxysmal Nocturnal Hemoglobinuria (PNH)\nEstimated primary completion: Dece
 mber 2028. This is a ClinicalTrials.gov estimate\, not a confirmed readout
  date\, and it can move.\nDrug page: https://assetmemo.bio/drug/pegcetacop
 lan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 04901936
URL:https://assetmemo.bio/drug/pegcetacoplan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT05646563-886@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20290731
DTEND;VALUE=DATE:20290801
SUMMARY:Soliris (Eculizumab): Phase 2 readout est. (NCT05646563)
DESCRIPTION:Soliris (Eculizumab)\, phase 2\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study of NM8074 in Adult PNH Patients With Inadequate Respo
 nse to Soliris\nEstimated primary completion: July 2029. This is a Clinica
 lTrials.gov estimate\, not a confirmed readout date\, and it can move.\nDr
 ug page: https://assetmemo.bio/drug/eculizumab#upcoming-events\nRegistry r
 ecord: https://clinicaltrials.gov/study/NCT05646563
URL:https://assetmemo.bio/drug/eculizumab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07187401-11297@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20291129
DTEND;VALUE=DATE:20291130
SUMMARY:ALN-CFB: Phase 1/2 readout est. (NCT07187401)
DESCRIPTION:ALN-CFB\, phase 1/2\, Paroxysmal Nocturnal Hemoglobinuria.\nStu
 dy: A First-in-Human Safety and Efficacy Study of ALN-CFB\, a Small Interf
 ering RNA (siRNA) Targeting Complement Factor B\, in Adult Participants Wi
 th Paroxysmal Nocturnal Hemoglobinuria With Persistent Anemia on a C5 Inhi
 bitor\nEstimated primary completion: 29 November 2029. This is a ClinicalT
 rials.gov estimate\, not a confirmed readout date\, and it can move.\nDrug
  page: https://assetmemo.bio/drug/aln-cfb#upcoming-events\nRegistry record
 : https://clinicaltrials.gov/study/NCT07187401
URL:https://assetmemo.bio/drug/aln-cfb#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07154745-5167@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20300118
DTEND;VALUE=DATE:20300119
SUMMARY:Veopoz (Pozelimab): Phase 3 readout est. (NCT07154745)
DESCRIPTION:Veopoz (Pozelimab)\, phase 3\, Paroxysmal Nocturnal Hemoglobinu
 ria.\nStudy: A Study to Evaluate How Pozelimab + Cemdisiran Combination Th
 erapy Works in Adult Patients With Paroxysmal Nocturnal Hemoglobinuria (PN
 H) Whose Current Treatment is Not Working Efficiently\nEstimated primary c
 ompletion: 18 January 2030. This is a ClinicalTrials.gov estimate\, not a 
 confirmed readout date\, and it can move.\nDrug page: https://assetmemo.bi
 o/drug/pozelimab#upcoming-events\nRegistry record: https://clinicaltrials.
 gov/study/NCT07154745
URL:https://assetmemo.bio/drug/pozelimab#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT06934967-887@assetmemo.bio
DTSTAMP:20261121T005223Z
DTSTART;VALUE=DATE:20311014
DTEND;VALUE=DATE:20311015
SUMMARY:Fabhalta (Iptacopan): Phase 3 readout est. (NCT06934967)
DESCRIPTION:Fabhalta (Iptacopan)\, phase 3\, Paroxysmal Nocturnal Hemoglobi
 nuria.\nStudy: Study to Assess the Pharmacokinetics\, Safety\, and Tolerab
 ility of Iptacopan in Pediatric PNH Patients\nEstimated primary completion
 : 14 October 2031. This is a ClinicalTrials.gov estimate\, not a confirmed
  readout date\, and it can move.\nDrug page: https://assetmemo.bio/drug/ip
 tacopan#upcoming-events\nRegistry record: https://clinicaltrials.gov/study
 /NCT06934967
URL:https://assetmemo.bio/drug/iptacopan#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
